Reduced fitness of HIV-1 resistant to CXCR4 antagonists

Antiviral Therapy

Volumn 8, Issue 1, 2003, Pages 1-8

  Armand Ugón, Mercedes ^a   Quiñones Mateu, Miguel E ^b   Gutiérrez, Arantxa ^a   Barretina, Jordi ^a   Blanco, Julià ^a   Schols, Dominique ^c   De Clercq, Erik ^c   Clotet, Bonaventura ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b LERNER RESEARCH INSTITUTE   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE COURSE; DNA SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRAIN DIFFERENCE; SUPERNATANT; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; CELL LINE; DRUG RESISTANCE, VIRAL; GIANT CELLS; HETEROCYCLIC COMPOUNDS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; RECEPTORS, CXCR4; SERIAL PASSAGE; VIRUS REPLICATION;

EID: 12244286063     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM & Berger EA. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
2. D'Souza MP & Harden VA. Chemokines and HIV-1 second receptors. Nature Medicine 1996; 2:1293-1300.
3. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J & Weiss RA. A new classification for HIV-1. Nature 1998; 391:240.
4. van't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C & Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. Journal of Virology 1998; 72:5099-5107.
5. Tersmette M, Lange JM, de Goede RE, de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, Coutinho RA, Huisman JG, Goudsmit J & Miedema F. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989; 1:983-985.
6. Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG & Miedema F. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Journal of Virology 1988; 62:2026-2032.
7. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-534.
8. Connor RI, Mohri H, Cao Y & Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. Journal of Virology 1993; 67:1772-1777.
9. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E & Moore JP. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Medicine 1998; 4:72-77.
10. Schols D, Struyf S, Van Damme J, Esté JA, Henson G & De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Journal of Experimental Medicine 1997; 186:1383-1388.
11. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D & De Clercq E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Journal of Virology 1999; 73:5577-5585.
12. Schols D, Esté JA, Cabrera C & De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. Journal of Virology 1998; 72:4032-4037.
13. De Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anne J, de Clercq E, Datema R & Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. Journal of Virology 1996; 70:689-696.
14. Bridger GJ, Skerlj RT, Thornton D, Padmanabhan S, Martellucci SA, Henson GW, Abrams MJ, Yamamoto N, De Vreese K, Pauwels R & De Clercq E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. Journal of Medicinal Chemistry 1995; 38:366-378.
15. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 1988; 20:309-321.
16. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, van Der Groen G, Colebunders RL & Arts EJ. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. Journal of Virology 2000; 74:9222-9233.
17. Este JA. HIV resistance to entry inhibitors. AIDS Reviews 2001; 1:121-132.
18. Este JA, De Vreese K, Witvrouw M, Schmit JC, Vandamme AM, Anne J, Desmyter J, Henson GW, Bridger G & De Clercq E. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Research 1996; 29:297-307.
19. Cabrera C, Gutierrez A, Blanco J, Barretina J, Litovchick A, Lapidot A, Evdokimov AG, Clotet B & Este JA. Antihuman immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. AIDS Research & Human Retroviruses 2000; 16:627-634.
20. De Vreese K, Van Nerum I, Vermeire K, Anne J & De Clercq E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrobial Agents & Chemotherapy 1997; 41:2616-2620.
21. Brelot A, Heveker N, Pleskoff O, Sol N & Alizon M. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. Journal of Virology 1997; 71:4744-4751.
22. Pleskoff O, Sol N, Labrosse B & Alizon M. Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin). Journal of Virology 1997; 71:3259-3262.
23. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J & Sodroski J. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. Journal of Virology 2000; 74:4433-4440.
24. Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, Manola J, Gelman R, Etemad-Moghadam B, Desjardins E, Wyatt R, Gerard NP, Marcon L, Margolin D, Fanton J, Axthelm MK, Letvin NL & Sodroski J. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. Journal of Experimental Medicine 1998; 188:1159-1171.
25. LaBonte JA, Patel T, Hofmann W & Sodroski J. Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. Journal of Virology 2000; 74:10690-10698.
26. Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E & Este JA. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 1999; 13:909-917.
27. Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B & Este JA. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface- expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrobial Agents & Chemotherapy 2000; 44:51-56.
28. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez AC & Mellado M. The chemokine SDF-1α triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB Journal 1999; 13:1699-1710.
29. Tilton B, Ho L, Oberlin E, Loetscher P, Baleux F, Clark-Lewis I & Thelen M. Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. Journal of Experimental Medicine 2000; 192:313-324.